Acarbose vs AOD-9604
A side-by-side research comparison of Acarbose and AOD-9604 across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Acarbose | AOD-9604 |
|---|---|---|
| Full name | Acarbose (Alpha-Glucosidase Inhibitor) | Advanced Obesity Drug Fragment 176-191 (Modified) |
| Category | Weight Management | Weight Management |
| Status | FDA-approved drug | Research compound |
| Mechanism | Inhibits intestinal alpha-glucosidase enzymes, slowing the breakdown of complex carbohydrates into glucose. This flattens post-prandial glucose and insulin excursions and shifts undigested carbohydrate to the colon, feeding beneficial short-chain-fatty-acid-producing bacteria. | Mimics the lipolytic domain of growth hormone (hGH 176-191), stimulating fat oxidation and inhibiting de novo lipogenesis through pathways independent of IGF-1 and growth signaling. |
| Molecular weight | 645.6 Da | 1815.08 Da |
| Half-life | ~2 hours | ~2-3 hours |
| Bioavailability | Very low systemic (~2%); acts locally in the gut | ~90% subcutaneous |
| Typical dose | 25-100 mg per meal | 300 mcg |
| Frequency | With carbohydrate-containing meals | Daily (morning, fasted) |
| Route | Oral tablet | Subcutaneous injection |
Acarbose reported benefits
- Flattens post-meal glucose spikes
- Improves glycemic variability
- Longevity signal (ITP data)
- Feeds beneficial gut bacteria
- Modest weight support
- Minimal systemic absorption
AOD-9604 reported benefits
- Fat loss without muscle wasting
- No effect on blood sugar
- Cartilage repair properties
- No HGH-related side effects
Related comparisons
Research and educational reference only. Not medical advice.